Local

Pfizer says 3 COVID shots protect children under 5. Here’s what to know about the vaccine.

Video above: Doctor discusses Moderna COVID-19 vaccine for infants Three doses of Pfizer COVID-19 vaccine provide strong protection for children under 5, the company said on Monday. Pfizer plans to report to U.S. authorities later this week in a move to allow children to get shot. The news comes after months of worrying parents are desperately trying to vaccinate their infants, toddlers and school-going children, especially as COVID-19. again they fly. 18 million tots under 5 are the only group in the United States still not eligible for COVID-19 vaccination. The Food and Drug Administration has begun evaluating data from Moderna’s rival, who hopes to start shooting for two children by the summer. Pfizer has a long way to go to find its way. He intended to give the right dose – one-tenth of the amount received by adults – but it was discovered during his experiment that the two shots were not very strong for school-going people. So the researchers gave a third shot to more than 1,600 teenagers – from 6 months to 4 years – during the cold season of the omicron variant. Antiretroviral measures that are sufficient to meet FDA requirements for emergency immunization without any safety concerns. Preliminary data show that the three-point formula is 80% effective in preventing COVID-19 symptoms, the companies said, but warned. the calculation is based on only 10 cases identified among study participants in late April. The research rules state that at least 21 times are required to ensure quality, and Pfizer promises to update as soon as more information is available. The companies have already submitted data on the first two doses to the FDA, and BioNTech CEO, Dr. Ugur Sahin, said the final third shooting data will be presented this week. “Studies have shown that a small, 3-microgram of our vaccine, carefully selected on the basis of patient data, gives young children a high level of protection against the disease. The most recent form of COVID-19,” he said in a statement. What’s next? FDA chief vaccinator Dr. Peter Marks promises the agency will “take it quickly without sacrificing our standards” in estimating the number of doses from both Pfizer and Moderna.The agency has set deadlines next month for scientific consultants to debate in public from all over the company.Moderna is looking to be the first to vaccinate young children. immunosuppressive measures after two shots containing one-fourth of the dose given to adults.A Moderna study found the effect of COVID-19 was 40% to 50% during omicon surgery, as in adults who received only two doses n adults.The FDA is expected to review Moderna data on both the youngest group age group, including adolescents and early adolescents. Some countries have already extended the Moderna shot to 6 children. While COVID-19 is generally not as safe for adolescents as for adults, some children suffer from illness or even death. And omicron variations affect children in particular, with those under 5 hospitalized at a higher cost than previous delta surgeries. It is unclear how much will be required to immunize young children. Pfizer injections for 5- to 11-year-olds were opened in November, but almost 30% of this age group recommended the first two doses. Last week, the U.S. Department of Health and Human Services said that children reaching first grade should get the stimulants shot as much as anyone 12 years of age and older should do, for best protection from new differences. -Different coronavirus. Department of Health Sciences. AP is solely responsible for all content.

The video above: Doctor discusses Moderna COVID-19 treatment for young children

A third of Pfizer’s COVID-19 vaccine provides strong protection for children under 5, the company said on Monday. Pfizer plans to report to U.S. authorities later this week in a move to let young children get shot.

The news comes after months of violence by parents against their infants, toddlers and school-going children, especially as COVID-19 cases escalated. 18 million tots under 5 are the only group in the United States who are not eligible for COVID-19 vaccination.

The Food and Drug Administration has begun assessing data from its rival Moderna, who hopes to start offering two shots to children in the summer.

Pfizer has more time to find its way. He intended to give the right dose – one-tenth of the amount received by adults – but it was discovered during his experiment that the two shots were not very strong for school-going people. So the researchers gave a third shot to over 1,600 teenagers – from 6 months to 4 years – during the winter climb of the omicron variant.

In a statement, Pfizer and partner BioNTech said the extra shot was a tactic, with the revival of immunosuppressive measures sufficient to meet FDA requirements to use emergency vaccines without any safety concerns. .

Preliminary data suggest that the three-point series is 80% effective in preventing COVID-19 symptoms, the companies said, but warned that the list is based on only 10 cases identified among study participants in late April. . The investigation rules state that at least 21 cases are required to assess the actual impact, and Pfizer promises to update as soon as more information is available.

The companies have already submitted data on the first two doses to the FDA, and BioNTech CEO Dr Ugur Sahin said the third and final data will be released this week.

“The study suggests that the small, 3-microgram of our vaccine, carefully selected based on patient data, provides infants with a high level of protection against the latest version of COVID-19,” she said. it in a statement.

What’s next? FDA chief vaccinator Dr. Peter Marks promised the agency would “speed up without compromising our standards” in estimating the number of doses from both Pfizer and Moderna.

The commission has set a deadline for next month for scientific advisers to debate in public from any company.

Moderna is looking to be the first to vaccinate young children. He presented data to the FDA saying that tots improve immunity levels after two shots which account for one-fourth of the total given to adults. Moderna studies found that the effect of COVID-19 was 40% to 50% during omicon climbing, similar to that of adults who only had two doses.

Improving Moderna’s development, the FDA has so far only allowed its vaccine to be used in adults.

The FDA is expected to review Moderna’s data on both the group’s minimum age group, and its analysis of adolescents and early teens. Some countries have already expanded the Moderna shooting for 6-year-olds.

While COVID-19 is generally not as safe for adolescents as for adults, some children become very ill or even die. And omicron variants hit kids especially hard, with those under 5 hospitalized at a much higher price than previous high-stakes extremists.

The extent of the need to vaccinate young children has not been disclosed. Pfizer injections for 5- to 11-year-olds were opened in November, but almost 30% of this age group recommended the first two doses. Last week, US health officials said that first-year children should get the booster shot as much as everyone 12 years of age should get, for the best protection against new strains of coronavirus. .

___

The Associated Press Department of Health and Science is funded by the Howard Hughes Center for Health Sciences. AP is solely responsible for all content.

Pfizer says 3 COVID shots protect children under 5. Here’s what to know about the vaccine. Source link Pfizer says 3 COVID shots protect children under 5. Here’s what to know about the vaccine.

Related Articles

Back to top button